Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiopulmonary Baroreflex Control of Renal Sympathetic Nerve Activity Is Impaired in Dogs With Left Ventricular Dysfunction.

Journal of cardiac failure·2019

Same author

Does the benefit from treating to lower blood pressure targets vary with age? A systematic review and meta-analysis.

Journal of hypertension·2019

Same author

History and Justification of a National Blood Pressure Measurement Validated Device Listing.

Hypertension (Dallas, Tex. : 1979)·2018

Same author

Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.

Journal of clinical hypertension (Greenwich, Conn.)·2018

Same author

Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution.

JACC. Basic to translational science·2018

Same author

Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis.

Journal of hypertension·2018

Search research articles

Related Experiment Videos

Pharmacologic Issues in treating hypertension in CKD.

Domenic A Sica¹

¹Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298-0160, USA. dsica@mcvh-vcu.edu

Advances in Chronic Kidney Disease

|January 13, 2011

Summary

Antihypertensive drugs manage high blood pressure (BP) in chronic kidney disease (CKD) patients. Careful drug selection and dosage are crucial due to kidney function impairment and potential adverse effects.

Related Experiment Videos

Area of Science:

Nephrology
Pharmacology
Cardiology

Background:

Chronic kidney disease (CKD) patients require antihypertensive medications.
Elevated blood pressure (BP) in CKD can accelerate kidney function loss and cause organ damage.
Proteinuria is a common comorbidity in CKD that requires management.

Purpose of the Study:

To review antihypertensive drug classes used in CKD management.
To highlight potential pitfalls in prescribing these drugs for CKD patients.
To emphasize the importance of dosage adjustments based on kidney function.

Main Methods:

Review of current antihypertensive drug classes.
Analysis of drug elimination pathways in impaired renal function.
Discussion of common adverse effects and management strategies.

Main Results:

Combination therapy, often involving diuretics and renin system inhibitors (ACE inhibitors, ARBs, ARAs), is frequently needed.
Many antihypertensive drugs are renally eliminated, necessitating dosage adjustments.
Impaired kidney function can alter drug efficacy and increase toxicity risk.

Conclusions:

Optimal BP control in CKD requires careful consideration of drug choice and dosage.
Understanding drug pharmacokinetics in CKD is essential to minimize adverse events.
Individualized treatment plans are necessary for effective and safe antihypertensive therapy in CKD.